<DOC>
	<DOCNO>NCT00086775</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , fludarabine , work different way stop cancer cell divide stop grow die . Monoclonal antibody , alemtuzumab rituximab , locate cancer cell either kill deliver cancer-killing substance without harm normal cell . Combining chemotherapy monoclonal antibody therapy may kill cancer cell . It yet know whether fludarabine effective combine alemtuzumab rituximab treat chronic lymphocytic leukemia . PURPOSE : Randomized phase II trial compare effectiveness combine fludarabine either alemtuzumab rituximab treat patient refractory relapse B-cell chronic lymphocytic leukemia .</brief_summary>
	<brief_title>Fludarabine Combined With Either Alemtuzumab Rituximab Treating Patients With Refractory Relapsed B-Cell Chronic Lymphocytic Leukemia</brief_title>
	<detailed_description>OBJECTIVES : Primary - Compare complete response rate patient refractory relapse B-cell chronic lymphocytic leukemia treat fludarabine alemtuzumab v fludarabine rituximab . Secondary - Compare overall response rate patient treat regimen . - Compare 1-year survival patient treat regimen . - Compare time progression patient treat regimen . - Compare duration response patient treat regimen . - Compare adverse event profile regimens patient . - Compare molecular response rate patient treat regimen . - Compare lymphocyte lymphocyte subset recovery ( CD3 , CD3/CD4 , CD3/CD8 , CD20 ) patient treat regimen . - Compare time complete response patient treat regimen . - Compare rate cytomegalovirus reactivation time reactivation patient treat regimen . OUTLINE : This randomize , open-label , multicenter study . Patients stratify accord prior treatment fludarabine ( yes v ) . Patients randomize 1 2 treatment arm . - Arm I : Patients receive fludarabine IV 30 minute day 1-5 . At least 30 minute fludarabine administration , patient receive alemtuzumab subcutaneously ( SC ) day 1-5 . - Arm II : Patients receive fludarabine arm I . At least 30 minute fludarabine administration , patient receive rituximab IV day 1 4 course 1 day 1 subsequent course . In arm , treatment repeat every 28 day 4-6 course absence disease progression unacceptable toxicity . An interim assessment perform course 4 . Patients achieve partial response stable disease receive 2 additional course therapy ( total 6 course ) . Patients achieve complete response ( CR ) receive treatment beyond CR . Patients follow weekly 2 month , monthly 6 month , every 2 month 6 month , every 6 month 1 year . PROJECTED ACCRUAL : A total 150 patient ( 75 per treatment arm ) accrue study .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Alemtuzumab</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis Bcell chronic lymphocytic leukemia ( CLL ) , define : Peripheral lymphocyte count &gt; 5,000/mm^3 Clonal CD5 , CD19 , CD23positive lymphocytes Refractory OR relapse prior firstline therapy No CNS involvement CLL PATIENT CHARACTERISTICS : Age 18 Performance status ECOG 02 Life expectancy Not specify Hematopoietic See Disease Characteristics Hepatic Bilirubin ≤ 1.5 time upper limit normal ( ULN ) Hepatitis B surface antigen negative Hepatitis C antibody negative Renal Creatinine ≤ 1.5 time ULN Immunologic No active cytomegalovirus No prior fludarabineassociated autoimmune hemolytic anemia immune thrombocytopenic purpura No active infection require treatment antibiotic , antiviral , antifungal agent No prior significant allergic reaction antibody therapy require therapy discontinue HIV negative Other No active secondary malignancy No concurrent severe diseases mental disorder Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy More 4 week since prior alemtuzumab and/or rituximab No prior bone marrow transplantation No concurrent thrombopoietin pegfilgrastim Chemotherapy More 3 week since prior fludarabine Endocrine therapy Not specify Radiotherapy Not specify Surgery Not specify Other More 3 month since prior investigational drug No concurrent cytotoxic therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2009</verification_date>
	<keyword>refractory chronic lymphocytic leukemia</keyword>
	<keyword>B-cell chronic lymphocytic leukemia</keyword>
</DOC>